ArticleFrontiers in pharmacology2026
The METOD study: exploring metabolism, emotional blunting and treatment outcomes in depression - A naturalistic, two-phase observational protocol.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Major depressive disorder (MDD) constitutes a substantial global health burden, profoundly undermining psychosocial functioning and quality of life, and the persistent limitations of treatment efficacy-despite advances in neurobiology and pharmacotherapy-underscore its considerable clinical complexity. Recent research increasingly delineates the heterogeneity of depressive symptomatology, particularly emotional blunting, and emerging evidence further implicates metabolic and inflammatory pathways processes in shaping treatment response Objectives: The study consists of two phases with distinct hypotheses: phase I) evaluating emotional blunting along other clinical/psychopathological variables as potential predictors of treatment non-response to SSRI/SNRI in MDD, and phase II) assessing relationships between IR and treatment non-response to vortioxetine in MDD. Further exploratory objectives encompass assessment of: links between psychopathological and metabolic predictors of health status; longitudinal association between emotional blunting and both sexual and cognitive functioning. Materials and Methods: The METOD study is an open, non-randomized two-phase observational study conducted in accordance with clinical standards and with all required ethical approvals. The protocol was prepared in line with STROBE recommendations. In Phase I, MDD patients meeting eligibility criteria and initiating antidepressant treatment with one of the first-line SSRIs or SNRIs are observed, whereas in Phase II, individuals showing an inadequate response are switched to vortioxetine as a second-line option. Validated clinical assessment tools are administered alongside anthropometric and laboratory evaluations. Expected Implications/Significance: By examining these interrelations within a naturalistic cohort treated in accordance with current clinical standards, this innovative study-with its strong emphasis on patient-reported outcomes-may increase insight into the lived experience of depression, enhance understanding of the pathophysiological mechanisms shaping its diverse symptomatology, and provide a foundation for more precisely targeted therapeutic approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.